Hospira, Inc, Initiates Recall of One Lot of 2% Lidocaine HCl Injection

 Hospira, Inc, of Lake Forest, IL, has initiated a voluntary recall for one lot of Lidocaine HCl Injection, USP 2%, 5 mL Single-Dose Vial, National Drug Code 0409-4276-01, Lot 32-135-DD due to the presence of particulate matter. Hospira initiated the recall after a reddish orange particulate was observed on the inner surface and floating in the solution. This recall is in addition to a similar recall of 1% Lidocaine HCI Injection that Hospira initiated on October 4, 2013. 

According to FDA, the recalled product was distributed to distributors/wholesalers, hospitals, and pharmacies located in Alaska, Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, Nevada, New Jersey, North Carolina, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas, Utah, Virginia, Washington, and Wisconsin between September 2013 and through October 2013. FDA advises that health care providers stop use and quarantine the product. To arrange return of the product, providers may call Stericycle at 866/364-8812 between the hours of 8 AM and 5 PM  ET, Monday through Friday. Adverse reactions may be reported to FDA’s MedWatch Safety Information and Adverse Event Reporting Program
quoted from here

Hospira issues 3 recalls as it faces crucial FDA inspection

February 27, 2013 | By Eric Palmer

Sterile injectables maker Hospira ($HSP) is having to recall lots of 5 different products even as FDA inspectors are in one of its plants conducting what the company hopes will be a final inspection that will return the drugmaker to the agency's good graces.
Over the last several days, Hospira recalled three lots of propofol injectable emulsion after reports came to light that some vials had visible particles embedded in the glass. These were found in some retained samples. It is recalling one lot of preservative-free morphine sulfate injection after a customer found either a loose crimp or no crimp on the flip-top vial, which raises the possibility of contamination. It also recalled three lots of diazepam injection, furosemide injection and Quelicin (succinylcholine chloride) injection for the same problem with loose crimping in flip tops.
The company said all of the recalls are voluntary and there have been no reports of patients being affected by any of the recalled products, although in each case there is a chance for serious effects.


Read more: Hospira issues 3 recalls as it faces crucial FDA inspection - FiercePharma http://www.fiercepharma.com/story/hospira-issues-3-recalls-it-faces-crucial-fda-inspection/2013-02-27#ixzz2MAnwvSbt
Subscribe: http://www.fiercepharma.com/signup?sourceform=Viral-Tynt-FiercePharma-FiercePharma